BOLD
Boundless Bio, Inc.
$1.43
+0.70%
$32.1M
No data for this timeframe.
Vol
Market Cap$32.1M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$4.5M
Inst. Activity1 buys / 0 sells
SEC Reports3
Press Releases1
Recent Activity
May 18, 2026
earnings_calendar
BOLD Q1 2026 Earnings Scheduled — 2026-05-18
May 8, 2026
SEC
Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate of $0.56 loss per sha
PRESS-RELEASE — Impact 6/10
May 8, 2026
SEC
Boundless Bio reported Q1 2026 results with a net loss of $13.6M, narrower than the $15.8M loss in Q1 2025, driven by lo
8-K — Impact 3/10
Apr 17, 2026
Press
Boundless Bio (BOLD) announced preclinical data for its lead candidate BBI-940, a novel oral kinesin degrader targeting
Impact 7/10
Apr 13, 2026
SEC
Boundless Bio terminated its lease for 80,168 square feet in San Diego effective May 31, 2026, originally set to expire
8-K — Impact 7/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
341,400 shares ($409.7K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
223,562 shares ($275.0K)
Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$4.00 (Aug 2025)
Current $1.40
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
0Strong Buy
0Buy
4Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 11, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jun 2, 2025 | HC Wainwright & Co. | INITIATE | Buy |
| May 28, 2025 | Leerink Partners | DOWNGRADE | Outperform → Market Perform |
| Dec 13, 2024 | Guggenheim | DOWNGRADE | Buy → Neutral |
| Apr 22, 2024 | Leerink Partners | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.60 ▼ -5.3% | $-0.62 — $-0.58 | 14% YoY | 3 |
| Next Q | $-0.63 ▼ -6.4% | $-0.67 — $-0.61 | -2% YoY | 3 |
| Current FY | $-2.38 | $-2.47 — $-2.27 | 8% YoY | 3 |
| Next FY | $-1.28 | $-1.92 — $-0.93 | 46% YoY | 3 |
Latest Reports
BEARISH
PRESS-RELEASE
6/10
Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate of $0.56 loss per sha
May 8, 2026
NEUTRAL
8-K
3/10
Boundless Bio reported Q1 2026 results with a net loss of $13.6M, narrower than the $15.8M loss in Q1 2025, driven by lo
May 8, 2026
BULLISH
Press
7/10
Boundless Bio (BOLD) announced preclinical data for its lead candidate BBI-940, a novel oral kinesin degrader targeting
Apr 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $3.2M | — |
| VANGUARD GROUP INC | $795.3K | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $409.7K | ADD |
| MORGAN STANLEY | $15.6K | TRIM |
| BANK OF AMERICA CORP | $9.3K | TRIM |
5 institutional holders with $4.5M total value (3,708,937 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, RENAISSANCE. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 2,684,022 | $3.2M | 72.4% | — |
| 2 | VANGUARD GROUP INC | 662,757 | $795.3K | 17.9% | ADD +75.7% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 341,400 | $409.7K | 9.2% | ADD +52.7% |
| 4 | MORGAN STANLEY | 13,000 | $15.6K | 0.4% | TRIM -53.6% |
| 5 | BANK OF AMERICA CORP /DE/ | 7,758 | $9.3K | 0.2% | TRIM -49.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 223,562 | 341,400 | +52.7% | $409.7K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 121,000 | 223,562 | +84.8% | $275.0K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 13 | 1 | -92.3% | $1.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 14,400 | 121,000 | +740.3% | $122.2K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 36,106 | 16,739 | -53.6% | $16.9K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 15,294 | 7,775 | -49.2% | $7.9K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 8,865 | 2,582 | -70.9% | $2.6K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 7,570 | 13 | -99.8% | $13.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 40,458 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 333,865 | 586,440 | +75.7% | $885.5K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 48,656 | 36,106 | -25.8% | $54.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 14,400 | — | $21.7K | 2025-Q1 |
| UBS Group AG | TRIM | 15,949 | 7,570 | -52.5% | $11.4K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 13,808 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 29,941 | 48,656 | +62.5% | $141.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 14,649 | 40,458 | +176.2% | $117.3K | 2024-Q4 |
| UBS Group AG | DOUBLED | 2,978 | 15,949 | +435.6% | $46.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 5,320 | 8,668 | +62.9% | $25.1K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 28,700 | 0 | -100.0% | $0.00 | 2024-Q4 |
| NORGES BANK | EXIT | 157,211 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 186,932 | 29,941 | -84.0% | $103.9K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 14,649 | — | $50.8K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
BEARISH
PRESS-RELEASE
6/10
Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate o
May 8, 2026
NEUTRAL
8-K
3/10
Boundless Bio reported Q1 2026 results with a net loss of $13.6M, narrower than the $15.8M loss in Q
May 8, 2026
BEARISH
8-K
7/10
Boundless Bio terminated its lease for 80,168 square feet in San Diego effective May 31, 2026, origi
Apr 13, 2026
Historical analyst distribution (last covering-analyst action Aug 2025): 0% buy across 7 analysts — 0 strong buy, 0 buy, 4 hold, 1 sell, 2 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$4.00 mean target (Aug 2025)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $1.40 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.60 | $-0.62 | $-0.58 | 14.3% | -5.3% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.63 | $-0.67 | $-0.61 | -2.1% | -6.4% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-2.38 | $-2.47 | $-2.27 | 8.5% | +0.1% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-1.28 | $-1.92 | $-0.93 | 46.2% | +0.3% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.600 | |
| 7d ago | $-0.570 | -0.030 |
| 30d ago | $-0.570 | -0.030 |
| 60d ago | $-0.570 | -0.030 |
| 90d ago | $-0.533 | -0.067 |
4 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 4 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 11, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jun 2, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
| May 28, 2025 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Dec 13, 2024 | Guggenheim | DOWNGRADE | Buy | Neutral |
| Apr 22, 2024 | Leerink Partners | INITIATE | — | Outperform |
| Apr 22, 2024 | Guggenheim | INITIATE | — | Buy |
| Apr 22, 2024 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
earnings_calendar
BOLD Q1 2026 Earnings Scheduled — 2026-05-18
May 8, 2026
earnings
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
<p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p>
Apr 17, 2026
fda
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for s
Mar 17, 2026
routine
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
<p align="justify">SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=n4yJbUKc4_pKyF-WdNRLKEje_o_6SIG
Mar 9, 2026
earnings
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
<p align="center"><em>KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment</em></p>
Mar 4, 2026
other
Boundless Bio to Participate in the Leerink Global Healthcare Conference
<p align="justify">SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YB5r86qFGBxIwj4gMK99MiUi6Zd5adO